Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
life sciences
national blog main
biotech
fda
boston blog main
drugs
akcea therapeutics
akouos
amgen
anylam pharmaceuticals
astellas pharmaceuticals
bempedoic acid
boston
boston top stories
calcitonin gene-related peptide
california institute for biomedical research
cardiomyopathy
cholesterol
chronic migraine
corticosteroids
deals
decibel therapeutics
detroit
detroit blog main
detroit top stories
eli lilly
episodic migraine
esperion therapeutics
ezetimibe
fluoroquinolones
frequency therapeutics
harvard university
hearing loss
indiana
indiana blog main
indiana top stories
inotersen
investing
jeffrey karp
What
approved
4
×
drug
4
×
fda
medicines
4
×
therapeutics
affects
ago
akcea
alnylam
americans
amyloidosis
announced
approval
attr
available
battle
cholesterol
class
combo
date
debilitating
decision
developed
developing
disease
eli
esperion
esperion’s
frequency
genetic
headache
hearing
ipo
late
levels
lilly
loss
lowering
marks
meds
Language
unset
Current search:
approved
×
medicines
×
drug
×
@xconomy.com
4 years ago
Esperion’s Combo Pill for Lowering Cholesterol Levels Wins FDA Nod
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com
4 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Eli Lilly Migraine Drug Approved, the Third in New Class of Medicines